19:57 , Oct 18, 2018 |  BC Extra  |  Company News

Management tracks: Autolus, Bayer, Cambridge Allergy

T cell cancer therapy company Autolus Therapeutics plc (NASDAQ:AUTL) hired Adam Hacker as SVP for regulatory affairs and quality, a newly created position. Previously, he was VP, head of vaccines and scientific innovation projects, global...
23:10 , Oct 17, 2018 |  BC Extra  |  Company News

Management tracks: Ziopharm, Merck

Immunotherapy company Ziopharm Oncology Inc. (NASDAQ:ZIOP) said CMO and EVP of R&D Francois Lebel will step down, effective Oct. 26. Merck & Co. Inc. (NYSE:MRK) hired Jim Scholefield as chief information and digital officer. He...
14:54 , Sep 11, 2018 |  BC Extra  |  Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...